Search results for "Benzimidazoles"

showing 10 items of 97 documents

Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease

2016

AbstractWe have reviewed the effects of angiotensin II type 1 receptor antagonists (ARBs) in various animal models of hypertension, atherosclerosis, cardiac function, hypertrophy and fibrosis, glucose and lipid metabolism, and renal function and morphology. Those of azilsartan and telmisartan have been included comprehensively whereas those of other ARBs have been included systematically but without intention of completeness. ARBs as a class lower blood pressure in established hypertension and prevent hypertension development in all applicable animal models except those with a markedly suppressed renin–angiotensin system; blood pressure lowering even persists for a considerable time after d…

0301 basic medicineBlood Pressure030204 cardiovascular system & hematologyKidneyurologic and male genital diseasesBenzoatesAnimals Genetically ModifiedRenin-Angiotensin SystemGene Knockout Techniques0302 clinical medicineAzilsartanPharmacology (medical)TelmisartanOxadiazolesKidneybiologyStrokemedicine.anatomical_structureCardiovascular DiseasesHypertensionDrug Therapy Combinationmedicine.drugmedicine.medical_specialty03 medical and health sciencesMetabolic DiseasesCulture TechniquesInternal medicineRenin–angiotensin systemmedicineAnimalsHumansAntihypertensive AgentsPharmacologyAngiotensin II receptor type 1business.industryAngiotensin-converting enzymeAtherosclerosisLipid Metabolismmedicine.diseaseDisease Models AnimalGlucose030104 developmental biologyBlood pressureEndocrinologyPathophysiology of hypertensionbiology.proteinBenzimidazolesEndothelium VascularTelmisartanbusinessAngiotensin II Type 1 Receptor BlockersPharmacology & Therapeutics
researchProduct

Morpho-functional study of vascular fluorochrome delivery to lung and liver metastases of Lewis lung carcinoma (3LL).

1991

The growth of 3LL liver and lung metastases related to Its vascular organization was studied by morphological and functional methods, using the Hoechst 33342 fluorescent DNA staining technique. Experimental liver and lung metastases were produced in syngeneic C57BL/6 mice by injection of 3LL tumor cells into a lateral tail vein or into the spleen, respectively. The resulting neoplasms were composed of large cells arranged in sheets with a thin irregularly distributed stroma. Scattered blood vessels with an open or closed lumen were observed within the tumor. Functional study of H33342 diffusion showed a single and reticular fluorescent pattern in liver metastases. In contrast, in lung meta…

0301 basic medicineCancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsLumen (anatomy)SpleenMetastasisMice03 medical and health sciences0302 clinical medicineStromaParenchymamedicineAnimalsFluorescent DyesLung030102 biochemistry & molecular biologybusiness.industryCarcinomaLiver NeoplasmsLewis lung carcinomaGeneral Medicinemedicine.diseaseMice Inbred C57BLPerfusionMicroscopy Electronmedicine.anatomical_structureOncology030220 oncology & carcinogenesisReticular connective tissueBenzimidazolesbusiness
researchProduct

In vivo fluorescent cercariae reveal the entry portals of Cardiocephaloides longicollis (Rudolphi, 1819) Dubois, 1982 (Strigeidae) into the gilthead …

2019

Background Despite their complex life-cycles involving various types of hosts and free-living stages, digenean trematodes are becoming recurrent model systems. The infection and penetration strategy of the larval stages, i.e. cercariae, into the fish host is poorly understood and information regarding their entry portals is not well-known for most species. Cardiocephaloides longicollis (Rudolphi, 1819) Dubois, 1982 (Digenea, Strigeidae) uses the gilthead seabream (Sparus aurata L.), an important marine fish in Mediterranean aquaculture, as a second intermediate host, where they encyst in the brain as metacercariae. Labelling the cercariae with in vivo fluorescent dyes helped us to track the…

0301 basic medicineGillCardiocephaloides longicollis030231 tropical medicineSuccinimidesZoologyAquacultureTrematode InfectionsCarboxyfluorescein diacetate succinimidyl esterDigeneaHost-Parasite Interactionslcsh:Infectious and parasitic diseasesFish Diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCercarial penetration patternCercarial survival and activityMetacercarial encystmentAnimalsHelminthsMetacercariaelcsh:RC109-216CercariaCardiocephaloides longicollisFluorescent DyesInfectivityLife Cycle StagesbiologyResearchIntermediate hostAquatic animalFluoresceinsbiology.organism_classificationSea Bream030104 developmental biologyInfectious DiseaseschemistryLarvaBenzimidazolesParasitologyTrematodaDigeneaParasites & Vectors
researchProduct

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

2018

Background & aims AASLD/IDSA treatment guidelines for hepatitis C virus (HCV) infection state that testing for quantitative HCV RNA can be considered at the end of antiviral treatment (EOT) with interferon-free regimens. However, it remains unclear how to respond to a detectable or even quantifiable HCV RNA result. The aim of this study was to analyse the frequency and predictive value of detectable and quantifiable HCV RNA results at the EOT in patients with HCV genotype 1 infection treated with ledipasvir (LDV) and sofosbuvir (SOF) ± ribavirin (RBV) in a large real-world cohort. Methods A retrospective analysis of the DHC-R (Deutsches Hepatitis C-Register, German Hepatitis C-Registry) coh…

0301 basic medicineLedipasvirMalemedicine.medical_specialtySofosbuvirSustained Virologic ResponseHepatitis C virusMedizinHepacivirusmedicine.disease_causeGastroenterologyAntiviral Agents03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineGermanyRibavirinMedicineHumansClinical significanceRegistriesRetrospective StudiesHepatitisFluorenesHepatologybusiness.industryRibavirinvirus diseasesHepatitis CViral Loadmedicine.diseaseHepatitis Cdigestive system diseases030104 developmental biologychemistryRNA Viral030211 gastroenterology & hepatologyBenzimidazolesFemaleSofosbuvirbusinessUridine MonophosphateViral loadmedicine.drug
researchProduct

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafen…

2020

Abstract Background BRAF/MEK inhibitor combinations are established treatments for BRAF V600–mutant melanoma based on demonstrated benefits on progression-free survival (PFS) and overall survival (OS). Here, we report an updated analysis of the COLUMBUS (COmbined LGX818 [encorafenib] Used with MEK162 [binimetinib] in BRAF mutant Unresectable Skin cancer) trial with long-term follow-up. Methods In part 1 of the COLUMBUS trial, 577 patients with advanced/metastatic BRAF V600–mutant melanoma, untreated or progressed after first-line immunotherapy, were randomised 1:1:1 to 450 mg of encorafenib QD + 45 mg of binimetinib BID (COMBO450) vs 960 mg of vemurafenib BID (VEM) or 300 mg of encorafenib …

0301 basic medicineOncologyMaleCancer ResearchSkin NeoplasmsMedizinchemistry.chemical_compound0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsOutcome Assessment Health CareMedicine1306 Cancer ResearchVemurafenibMelanomaAged 80 and overSulfonamidesMEK inhibitorMelanomaHazard ratio10177 Dermatology ClinicBinimetinibNauseaMiddle AgedPrognosisOncologyTolerability030220 oncology & carcinogenesis2730 OncologyFemalemedicine.drugAdultDiarrheaProto-Oncogene Proteins B-rafmedicine.medical_specialtyVomiting610 Medicine & healthDisease-Free Survival03 medical and health sciencesInternal medicineHumansneoplasmsAgedbusiness.industrymedicine.diseaseConfidence interval030104 developmental biologychemistryVemurafenibMutationBenzimidazolesCarbamatesSkin cancerbusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer?

2018

Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients and Methods A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo 40 mg twice daily, days 1 to 7, and oral TMZ 150 to 200 mg/m

0301 basic medicineOncologyMaleLung NeoplasmsDNA Mutational AnalysisPoly (ADP-Ribose) Polymerase-1Placebos0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsPromoter Regions GeneticDNA Modification MethylasesAged 80 and overStandard treatmentNuclear ProteinsMiddle AgedNeoplastic Cells CirculatingImmunohistochemistryhumanitiesEditorialOncology030220 oncology & carcinogenesisFemaleNon small cellAdultmedicine.medical_specialtyMEDLINEAggressive disease03 medical and health sciencesText miningDouble-Blind MethodInternal medicinemedicineBiomarkers TumorTemozolomideHumansLung cancerneoplasmsAntineoplastic Agents AlkylatingAgedbusiness.industryTumor Suppressor ProteinsDNA Methylationmedicine.diseaseSmall Cell Lung Carcinomarespiratory tract diseases030104 developmental biologyDNA Repair EnzymesBenzimidazolesPersonalized medicinebusiness
researchProduct

Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome

2020

Background: Familial chylomicronemia syndrome (FCS) is characterized by severe fasting hypertriglyceridemia, abdominal pain, and recurrent acute pancreatitis. Available triglyceride-lowering drugs are insufficient to avoid pancreatitis. Therefore, there is a significant unmet medical need for effective triglyceride-lowering drugs for patients with FCS. Case report: We report the second case of a patient with FCS and recurrent pancreatitis treated with lomitapide. Lomitapide treatment resulted in a reduction of fasting TG levels from 2897 mg/dL (32.71 mmol/L) to an average of 954 mg/dL (10.77 mmol/L) on the 30 mg lomitapide equating to a 67% reduction from baseline. After 26 months of lomita…

Abdominal painPediatricsmedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyRecurrent pancreatitisInternal medicineFatty liverHumansMedicineProspective Studiesmedicine.diagnostic_testbusiness.industryFatty liverHypertriglyceridemiaFCSFamilial Chylomicronemiamedicine.diseaseLomitapideLomitapideAcute pancreatitisPancreatitischemistry030220 oncology & carcinogenesisLiver biopsyAcute DiseaseAcute pancreatitisPancreatitisBenzimidazolesHyperlipoproteinemia Type Ilipids (amino acids peptides and proteins)medicine.symptomCardiology and Cardiovascular MedicinebusinessFamilial chylomicronaemia syndromeAtherosclerosis
researchProduct

Effect of histamine and histamine analogues on human isolated myometrial strips.

1992

1. The effect of histamine and histamine H1- and H2-receptor agonists on isolated myometrium strips of premenopausal women has been examined. The effect of acetylcholine was also determined. 2. Histamine, 2-pyridylethylamine, 4-methylhistamine and acetylcholine, but not dimaprit, produced a concentration-related contractile response in human isolated myometrial strips. Histamine also produced a further contraction in human isolated myometrial strips precontracted with KCl (55 mM). 3. The contractile response to histamine was antagonized by the histamine H1-receptor antagonist, clemizole (0.1 microM) but was potentiated by the histamine H2-receptor antagonist, ranitidine (10 microM). Clemizo…

AdultAtropinemedicine.medical_specialtyPyridinesMuscle RelaxationHistamine H1 receptorRanitidineHistamine agonistPotassium ChlorideHistamine Agonistschemistry.chemical_compoundHistamine receptorUterine ContractionHistamine H2 receptorInternal medicinemedicineHumansPharmacologyDose-Response Relationship DrugMethylhistaminesMuscle SmoothMiddle AgedDimapritAcetylcholineClemizoleEndocrinologyMuscle relaxationchemistryMyometriumBenzimidazolesFemaleHistamineHistamineResearch ArticleBritish journal of pharmacology
researchProduct

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

2019

Background and aims Chronic hepatitis C virus (HCV) infection increases the risk of incident chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD). Previously available direct-acting antiviral regimens are not approved for patients with advanced CKD across all HCV genotypes. Methods EXPEDITION-5 is a phase 3 study to evaluate efficacy and safety of the fixed-dose combination of glecaprevir and pibrentasvir (G/P) for chronic HCV infection (genotype 1 through 6) in adults without cirrhosis or with compensated cirrhosis and with stage 3b, 4 or 5 CKD. Patients received approved duration of G/P according to HCV genotype, cirrhosis status and prior HCV treatment experienc…

AdultCyclopropaneshepatitis C virusmedicine.medical_specialtyAminoisobutyric AcidsPyrrolidinesCirrhosisProlineLactams Macrocyclicmedicine.medical_treatmentAntiviral Agents03 medical and health sciences0302 clinical medicineLeucineQuinoxalinesInternal medicineGenotypeHumansMedicineAdverse effectDialysisSulfonamidesdirect-acting antiviralpangenotypicHepatologychronic kidney disease; cirrhosis; direct-acting antiviral; hepatitis C virus; pangenotypicbusiness.industrycirrhosisGlecaprevirHepatitis C Chronicmedicine.diseasePibrentasvirDrug Combinations030220 oncology & carcinogenesisBronchitisBenzimidazoles030211 gastroenterology & hepatologybusinesschronic kidney diseaseKidney disease
researchProduct

Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment

2009

A novel cancer stem-like cell line (3AB-OS), expressing a number of pluripotent stem cell markers, was irreversibly selected from human osteosarcoma MG-63 cells by long-term treatment (100 days) with 3-aminobenzamide (3AB). 3AB-OS cells are a heterogeneous and stable cell population composed by three types of fibroblastoid cells, spindle-shaped, polygonal-shaped, and rounded-shaped. With respect to MG-63 cells, 3AB-OS cells are extremely smaller, possess a much greater capacity to form spheres, a stronger self-renewal ability and much higher levels of cell cycle markers which account for G1-S/G2-M phases progression. Differently from MG-63 cells, 3AB-OS cells can be reseeded unlimitedly wit…

AdultHomeobox protein NANOGAdolescentPhysiologyCellular differentiationClinical BiochemistryApoptosisBiologyStem cell markerYoung Adultcancer stemm cells osteosarcoma PARP inhibitorsCancer stem cellCell Line TumorSettore BIO/10 - BiochimicaHumansRhodamine 123Enzyme InhibitorsProgenitor cellChildInduced pluripotent stem cellCell ShapeCell potencyFluorescent DyesOsteosarcomaCell DifferentiationCell BiologyCalcium Channel BlockersDrug Resistance MultipleGene Expression Regulation NeoplasticVerapamilBenzamidesImmunologyNeoplastic Stem CellsCancer researchATP-Binding Cassette TransportersBenzimidazolesStem cellBiomarkersJournal of Cellular Physiology
researchProduct